Session Information

EP02.04-009 - Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC

EP03.01-002 - Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations

EP03.01-016 - The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration

EP04.01-001 - Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience

EP08.01-067 - Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC

EP08.02-082 - Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study

EP08.02-118 - TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors

EP11.02-001 - Natural Language Processing to Abstract Preneoplastic and Incidental Pulmonary Lesions from Pathology Reports

EP14.01-019 - Identifying Circulating DNA Methylation Patterns in Small Cell Lung Cancer Patients

EP14.04-001 - Treatment and Outcomes of Patients with Limited-Stage Small-cell Lung Cancer in the Canadian SCLC Database (CASCADE)

EP14.05-020 - Population-based Outcomes for Patients with Extensive-Stage Small-cell Lung Cancer from the Canadian SCLC Database (CASCADE)

MA14.08 - Longitudinal Symptoms and Health Utility Scores (HUS) in Patients Receiving PD-1 Inhibitors for Metastatic NSCLC

15:02 - 15:07  |  Presenter: Christopher Poletes